Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-03-27
2007-03-27
Switzer, Juliet C. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
10331192
ABSTRACT:
Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.
REFERENCES:
patent: 6043031 (2000-03-01), Koster et al.
patent: 6498009 (2002-12-01), Liggett
patent: 2002/0187491 (2002-12-01), Johnson
patent: 2005/0181386 (2005-08-01), Diamond et al.
patent: WO 99/19512 (1999-04-01), None
Ferrari et al. “Genetic mapping and tailored antihypertensive therapy”, Cardiovascular Drugs and Therapy, vol. 14, No. 4, pp. 387-395, 2000.
White et al. “Update on the drug treatment of hypertension in patients with cardiovascular disease”, The American Journal of Medicine, vol. 118, pp. 695-705, 2005.
Mellen et al. “Pharmacogenomics of blood pressure response to antihypertensive treatment”, Journal of Hypertension, vol. 23, pp. 1311-1325, 2005.
Karlsson et al. Beta-1 adrenergic receptor gene polymorphisms and response to beta-1 adrenergic receptor blockade in patients with essential hypertension, Clinical Cardiology, vol. 27, No. 6, Suppl. 3, pp. 347-350, 2004.
Filigheddu et al. “Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade”, The Pharmacogenomics Journal, vol. 4, pp. 154-160, 2004.
Johnson et al. “Beta-1 adrenergic receptor polymorphisms and antihypertensive response to metoprolol”, Clinical Pharmacology & Therapeutics, vol. 74, pp. 44-52, 2003.
Brain et al. “Pharmacogenomics in hypertension: present practicalities and future potential”, Journal of Hypertension, vol. 23, pp. 1327-1329, 2005.
Liljedahl et al. “A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response”, Pharmacogenetics, vol. 13, pp. 7-17, 2003.
Filigheddu et al. “Genetic polymorphisms of the beta-adrenergic receptor system are not associated with essential hypertension and do not predict the effect of beta-blockers in a north Sardinian cohort”, J. Hypertension, vol. 20, Supp.[4], p. S19, 2002.
Leineweber “Beta-adrenergic receptor polymorphism in human cardiovascular disease”, Annals of Medicine, vol. 36, Suppl. 1, pp. 64-69, 2004.
Lizardi et al. “Mutation detection and single-molecule counting using isothermal rolling-circle amplification”, Nature genetics, vol. 19, pp. 225-232, 1998.
Hessner et al. “Genotyping of Factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes”, Clinical Chemistry, vol. 46, No. 8, pp. 1051-1056, 2000.
Wikipedia entry entitled “Thiazide” from Wikipedia, the free encyclopedia, accessed May 30, 2006 at http://en.wikipedia.org/wiki/Thiazide, 2 pages.
Piazza, Alberto, “Who Are the Europeans?”,Science, Jun. 18, 1993; 260:1767-1769.
Hingorani, Aroon D., et al., “Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition”,Journal of Hypertension, 1995; 13:1602-1609.
Haiyan, Jia, et al., “Association of the Gsα Gene With Essential Hypertension and Response to β-Blockade”,Hypertension, 1999; 34:8-14.
Glorioso, Nicola, et al., “The Role of α-Adducin Polymorphism in Blood Pressure and Sodium Handling Regulation May Not Be Excluded by a Negative Association Study”,Hypertension, 1999; 34:649-654.
Borjesson, M., et al., “A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure”,European Heart Journal, 2000; 21:1853-1858.
Podlowski, Svenia, et al., “β1-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy?”,J. Mol. Med., 2000; 78:87-93.
Samani, N.J., “Pharmacogenomics of hypertension: a realizable goal?”,Clinical Science, 2000; 99:231-232.
Wolf, C Roland, et al., “Science, medicine, and the future—Pharmacogenetics”,BMJ, Apr. 8, 2000; 320:987-990.
Drysdale, Connie M., et al., “Complex promoter and coding region β2- adrenergic receptor haplotypes alter receptor expression and predictin vivoresponsiveness”,PNAS, Sep. 12, 2000; 97(19):10483-10488.
Turner, Stephen T., et al., “Antihypertensive pharmacogenetics: getting the right drug into the right patient”,Journal of Hypertension, 2001; 19:1-11.
Bengtsson, Kristina, et al., “Polymorphism in the β1-Adrenergic Receptor Gene and Hypertension”,Circulation, 2001; 104:187-190.
Ranade, Koustubh, et al., “A Polymorphism in the β1 Adrenergic Receptor Is Associated with Resting Heart Rate”,Am. J. Hum. Genet., 2002; 70:935-942α.
Filigheddu Fabiana
Reid Julia
Wagner Susanne
Myriad Genetics Inc.
Myriad Genetics IP Dept.
Switzer Juliet C.
Zhang Jay Z.
LandOfFree
Drug response marker in beta-1 adrenergic receptor gene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug response marker in beta-1 adrenergic receptor gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug response marker in beta-1 adrenergic receptor gene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3799168